DDInter1066 DDInter534
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016 . Combining diazepam, a proven effective therapy for acute repetitive seizures, with an auto-injector designed for subcutaneous administration that is quickly and easily administered offers the potential for complete, consistent drug absorption and rapid onset of effect . This current development is subsequently an important addition to the rescue therapy tool chest for patients with epilepsy .
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quazepam
Quazepam {u} (Compound) resembles {v} (Compound) Diazepam
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxazepam
Oxazepam {u} (Compound) resembles {v} (Compound) Diazepam
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorazepam
Lorazepam {u} (Compound) resembles {v} (Compound) Diazepam
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Oxcarbazepine
Oxcarbazepine {u} (Compound) resembles {v} (Compound) Diazepam
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Temazepam
Temazepam {u} (Compound) resembles {v} (Compound) Diazepam
Lidocaine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Diazepam
Lidocaine {u} (Compound) causes {v} (Side Effect) Chills
Chills {u} (Side Effect) is caused by {v} (Compound) Diazepam
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quazepam
Quazepam {u} (Compound) resembles {v} (Compound) Flunitrazepam
Flunitrazepam {u} (Compound) resembles {v} (Compound) Diazepam
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxazepam
Oxazepam {u} (Compound) resembles {v} (Compound) Bromazepam
Bromazepam {u} (Compound) resembles {v} (Compound) Diazepam
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorazepam
Lorazepam {u} (Compound) resembles {v} (Compound) Quazepam
Quazepam {u} (Compound) resembles {v} (Compound) Diazepam
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Diazepam (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Oxazepam and Oxazepam (Compound) resembles Diazepam (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Diazepam (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Diazepam (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Temazepam and Temazepam (Compound) resembles Diazepam (Compound)
Lidocaine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Diazepam (Compound)
Lidocaine (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Diazepam (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Flunitrazepam (Compound) and Flunitrazepam (Compound) resembles Diazepam (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Oxazepam and Oxazepam (Compound) resembles Bromazepam (Compound) and Bromazepam (Compound) resembles Diazepam (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Lorazepam and Lorazepam (Compound) resembles Quazepam (Compound) and Quazepam (Compound) resembles Diazepam (Compound)